These results suggest that BCL-XL is a key pro-survival protein in SCLC and DT2216 might have a broad-spectrum antitumor activity than a BCL-XL inhibitor in killing BCL-XL-dependent SCLC cells. This evidence concerns the gene BCL2L1 and small cell lung carcinoma.